Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 1.00 |
| ▸ | MMP1 | P03956 | 3/20 | 1.00 |
| ▸ | MMP9 | P14780 | 12/20 | 0.69 |
| ▸ | MMP14 | P50281 | 9/20 | 0.69 |
| ▸ | MMP3 | P08254 | 4/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 6/20 | 0.48 |
| ▸ | MMP7 | P09237 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297772 | 0.85 | MMP2 (0.73) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL12717520 | 0.85 | MMP2 (0.74) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL313439 | 0.83 | MMP2 (0.71) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL12717348 | 0.82 | MMP2 (0.69) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL315716 | 0.82 | MMP2 (1.00) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL4292169 | 0.80 | MMP2 (0.67) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL14727900 | 0.78 | MMP2 (0.64) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL10187462 | 0.77 | MMP2 (0.67) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL4199837 | 0.76 | MMP2 (0.61) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL8781070 | 0.76 | MMP2 (0.61) | MMP2MMP1MMP9MMP14MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204170-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT, FOR LUNG INFLAMMATION AND FIBROSIS, CONTAINING COMPOUND HAVING MMP2 INHIBITORY ACTIVITY AS ACTIVE INGREDIENT | 大正製薬株式会社 | 2023-10-26 | — | — | WO | disclosed |
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | 712 NORTH INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2021119183-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | 712 NORTH, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-8828977-B2 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2012112945-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS TO TREAT TUBERCULOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-08-23 | — | — | WO | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20070190149-A1 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2006125208-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | MMP2 3/4885MMP1 2/4885MMP9 1/4885 |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | MMP2 3/4885MMP1 2/4885MMP9 1/4885 |
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | OPA1, OLA1, ACOX1 | MMP2 3600/4885MMP1 3236/4885MMP9 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.